score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.191	267.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	63.0	0.4444	0.9979	BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.L770F	0.0618	178.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0	0.0	0.0	0.0	EGFR p.L770F (Missense)	1.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.E588K	0.1359	390.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf													0	0.0	0.0	0.0	FGFR3 p.E588K (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G668E	0.1066	122.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf													0	0.0	0.0	0.0	FGFR3 p.G668E (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	Guideline			Rearrangement	COL1A1	Fusion	COL1A1--SPTBN1			0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf													0				COL1A1--SPTBN1 Fusion	1.0	MEL-IPI_Pat38		
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.V242I	0.1258	151.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056													0	38.0	0.1842	0.7194	ERCC2 p.V242I (Missense)	0.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.L531F	0.2821	39.0	8e-06	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763													0	134.0	0.5597	1.0	ARAF p.L531F (Missense)	0.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat38		
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Splice Site		0.0611	131.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0	6.0	0.6667	0.0005	PTEN  (Splice Site)	1.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.G687E	0.0561	481.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981													0	79.0	0.1519	0.659	FBXW7 p.G687E (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.G644E	0.0892	269.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981													0	62.0	0.2742	0.8064	FBXW7 p.G644E (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.G197E	0.0927	151.0	4.1e-05	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0	184.0	0.3696	0.9992	ATM p.G197E (Missense)	1.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.P2907S	0.1254	311.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007													0	243.0	0.6379	1.0	ATM p.P2907S (Missense)	1.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P684L	0.1311	61.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf						0	26.0	0.3077	0.4979	ABL1 p.P684L (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.G588R	0.0782	307.0	0.0	0.0																Investigate Actionability	0.0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	55.0	0.4182	0.6401	SETBP1 p.G588R (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.A1369T	0.0714	84.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	88.0	0.2045	0.8491	BRCA1 p.A1369T (Missense)	1.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Splice Site	p.C558Y	0.0994	463.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	EZH2 p.C558Y (Splice Site)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	FDA-Approved		Clinical trial	Somatic Variant	PIK3CA	Splice Site		0.0533	150.0	0.0	0.0		Investigate Actionability	Alpelisib	PI3K/AKT/mTOR inhibition	Targeted therapy	Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. 	Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf								Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0	1.0	1.0	0.0	PIK3CA  (Splice Site)	1.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Splice Site		0.136	125.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0	12.0	0.3333	0.0867	BARD1  (Splice Site)	0.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.G16E	0.0636	173.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0	67.0	0.209	0.6416	CHEK1 p.G16E (Missense)	1.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.T166I	0.1261	341.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0	55.0	0.1091	0.9195	BRIP1 p.T166I (Missense)	1.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.G94D	0.1338	157.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0	94.0	0.3298	0.9964	TSC1 p.G94D (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Splice Site	p.K42K	0.1304	230.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135													0	0.0	0.0	0.0	ERRFI1 p.K42K (Splice Site)	0.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.L147F	0.0844	154.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0	110.0	0.4273	0.9687	MSH6 p.L147F (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.G1157D	0.0822	146.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0	82.0	0.5122	0.8886	MSH6 p.G1157D (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.A750V	0.0807	223.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951													0	0.0	0.0	0.0	PBRM1 p.A750V (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.A656V	0.162	179.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0.0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0	239.0	0.4226	1.0	ARID1A p.A656V (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Nonsense	p.R451*	0.1795	39.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687													0	110.0	0.0	0.9988	JAK3 p.R451* (Nonsense)	0.0	MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.A215T	0.0824	449.0	0.0	0.0																Investigate Actionability	0.0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	226.0	0.1593	0.9999	ETV6 p.A215T (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.P107L	0.0796	113.0	0.0	0.0																Investigate Actionability	0.0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	285.0	0.1719	0.9997	PTPN11 p.P107L (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41N	0.0992	121.0	0.0	0.0																Investigate Actionability	1.0	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324	0	1639.0	0.4277	1.0	CTNNB1 p.T41N (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Biologically Relevant				Somatic Variant	MTOR	Missense	p.T1346I	0.0746	268.0	0.0	0.0																					0	139.0	0.3525	0.9856	MTOR p.T1346I (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G368D	0.2157	51.0	0.0	0.0																					0	2.0	1.0	0.0	NTRK1 p.G368D (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.R245Q	0.1235	81.0	8.3e-05	0.0																					0	0.0	0.0	0.0	SLC45A3 p.R245Q (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.G997D	0.1603	156.0	0.0	0.0																					0	218.0	0.0046	1.0	PDGFRB p.G997D (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Biologically Relevant				Somatic Variant	POT1	Missense	p.T217I	0.0627	255.0	0.0	0.0																					0	47.0	0.2553	0.3762	POT1 p.T217I (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.A579T	0.0922	141.0	0.0	0.0																					0	0.0	0.0	0.0	FGFR1 p.A579T (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Biologically Relevant				Somatic Variant	PAK1	Missense	p.P15L	0.0345	261.0	0.0	0.0																					0	40.0	0.0	0.0778	PAK1 p.P15L (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Biologically Relevant				Somatic Variant	RB1	Missense	p.G581R	0.1229	179.0	0.0	0.0																					0	234.0	0.3504	1.0	RB1 p.G581R (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Biologically Relevant				Somatic Variant	NF1	Missense	p.A1098V	0.0467	150.0	0.0	0.0																					0	170.0	0.1765	0.9243	NF1 p.A1098V (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.V62I	0.1362	756.0	8e-06	0.0																					0	3553.0	0.0003	1.0	COL1A1 p.V62I (Missense)		MEL-IPI_Pat38	MEL-IPI_Pat38-Tumor-SM-53U3Z	MEL-IPI_Pat38-Normal-SM-53U5L
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat38		
Biologically Relevant				Mutational Signature	COSMIC Signature 11	version 2	0.862																									0				COSMIC Signature (version 2) 11 (86%)		MEL-IPI_Pat38		
